HER-2/neu genotype of breast cancer may change in bone metastasis

Lörincz, Tamás; Tóth, József; Badalian, Gayane; Tı́már, József; Szabó, Miklós

doi:10.1007/bf02893361

Cited by 31 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors suggested that the decrease in immunoreactivity may be a possible misclassification of the IHC 2þ score patients not confirmed by FISH. In addition, Lorincz and colleagues (30) found that half of PBC with HER2 amplification lost this genotype in the correspondent bone metastases. Furthermore, even though HER2 amplification was retained in the MBC, the copy number decreased compared to the primary tumor.…”

Section: Discussionmentioning

confidence: 97%

“…Some authors reported that the specimens were handled as part of routine clinical care and were not restained, but rather reread by at least 2 pathologists according to the initial procedures (either IHC or FISH). Retesting was done in cases considered unsuitable for re-evaluation (9,10,30). In other studies HER2 status was assayed on histological samples in PBC and on cytological samples in MBC (13,28,29).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

Fabi¹,

Benedetto²,

Metro³

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression.Experimental Design: HER2 was investigated by immunohistochemistry, silver in situ hybridization (SISH), and FISH, in a series of 137 tumors, building up a tissue microarray to concurrently analyze each single PBC and metastatic (MBC) on the same slide.Results: HER2 status was discordant in 14 cases (10%): 12 negative in PBC and positive in metastases and two positive in PBC and negative in metastases (P ¼ 0.04). These findings were confirmed by a PCR based test termed Multiplex Ligation-dependent Probe Amplification (MLPA). HER2 status changed in hormone receptor-positive BC more frequently than in negative ones (P ¼ 0.002). In addition, we evaluated HER2 gene and chromosome 17 copy number by SISH in the 123 cases with unchanged HER2 status during progression. We found consistent HER2 gene copy number stability in the 100 nonamplified cases. Conversely, of the 23 amplified PBC, 13 (57%) demonstrated a significant increase in the HER2 gene and chromosome 17 copy number in their paired metastases (P ¼ 0.01), as defined by SISH (k ¼ 0.54, P < 0.0001) and MLPA. Patients who changed HER2 status from negative to positive, presented significant longer time to progression when treated with trastuzumab compared to those who were untreated (P ¼ 0.04).Conclusions: When feasible, HER2 reassessment in metastatic lesions should be carefully taken into account, especially for metastases coming from primary hormone receptor-positive BC.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

Fabi¹,

Benedetto²,

Metro³

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that discordance of ER and Her2 expression between primary and metastasis can occur [8,[10][11][12][13][14][15]. However, the degree of discordance reported is highly variable between studies, and many of these studies used different cutoff values and methodologies to define ER and Her2 positivity.…”

Section: Introductionmentioning

confidence: 98%

Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis

et al. 2012

View full text Add to dashboard Cite

“…Such differences in proteins/genes expressions between primary tumor and metastasis were also reported in other cancer types. Indeed, in breast cancer 30% of patients showed discordance in estrogen receptor expression [16] and 50% showed loss of HER-2/neu amplification status between primary tumor and corresponding metastasis [17]. In colon cancer, 55% of discordance were found in EGFR expression levels [18] and no correlation was found in gene expression levels of several enzymes related to response to 5-Fluorouracil therapy between primary tumor and corresponding metastasis [19].…”

Section: Discussionmentioning

confidence: 98%

Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases

Raynaud

Mercier

Commo³

et al. 2009

Lung Cancer

View full text Add to dashboard Cite

HER-2/neu genotype of breast cancer may change in bone metastasis

Cited by 31 publications

References 20 publications

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis

Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases

Contact Info

Product

Resources

About